Online Purchasing Account You are logged on as Guest. LoginRegister a New AccountShopping cart (Empty)
United States 

DR3 (human):Fc (human), (recombinant)

ALX-522-040-C050 50 µg 536.00 USD
Do you need bulk/larger quantities?

Product Details

Alternative Name:WSL-1, Apo-3, LARD, TRAMP, TR3, TNFRSF 12, TNFRSF 25, Death receptor 3
MW:~55kDa (under reducing conditions).
Source:Produced in HEK 293 cells. The cysteine-rich region of human DR3 (aa 25-199) is fused to the Fc portion of human IgG1.
UniProt ID:Q93038
Concentration:1mg/ml after reconstitution.
Formulation:Lyophilized. Contains PBS.
Purity:≥95% (SDS-PAGE)
Endotoxin Content:<0.1EU/µg purified protein (LAL test; Bio Whittaker).
Specificity:Binds human TL1A.
Application Notes:Can be used together with anti-human IgG1 PAb to detect TL1A.
Reconstitution:Reconstitute with 50µl sterile water. Further dilutions should be made with medium containing 5% fetal calf serum or a carrier protein.
Shipping:Blue Ice
Long Term Storage:-20°C
Use/Stability:Stable for at least 6 months after receipt when stored at -20°C. After reconstitution, it is recommended to make appropriate aliquots and to store them at -20°C.
Handling:Avoid freeze/thaw cycles.
Scientific Background:The DR3 receptor (WSL-1, Apo-3, LARD, TRAMP, TR3) is a member of the tumor necrosis factor receptor (TNF-R) family. DR3 is a type I transmembrane receptor. It is 339 aa long and contains 4 extracellular cysteine-rich motifs in its extracellular domain, while its cytoplasmic region contains a death domain. DR3 is abundantly expressed on thymocytes and T and B lymphocytes. Overexpression of DR3 mediates activation of nuclear factor NF-κB and induces apoptosis. Besides the induction of apoptosis, DR3 has been reported to regulate negative selection during thymocyte development.
Regulatory Status:RUO - Research Use Only

Related Products

Control:Fc fusion protein (human), (recombinant) 

Negative control for Fc chimeric proteins
Produced in HEK 293 cells. The extracellular domain of mutated hThy-1, hThy-1 (RLE) (aa 20-130), is fused to the Fc portion of human IgG1. The integrin binding sequence RLD of hThy-1 has been changed to RLE abolishing the binding of integrins., ≥90% (SDS-PAGE) | Print as PDF
ALX-203-004-C050 50 µg 532.00 USD
Do you need bulk/larger quantities?

Product Toolbox


Certificate of Analysis


By target:
Death receptor
By biological activity:
Death receptor Recombinant protein
By catalog section:


Technical Service
Customer Service